NERV

Minerva Neurosciences Inc. (NERV) | Rumor.io

Minerva Neurosciences

NERV

Attention (50-day avg)0%

Attention rank (50-day avg)#4,172

Bullish sentiment (50-day avg)100%

Price to earnings ratio2.51

Market capitalization162.3M

Earnings per share-36.1

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-293.4M

Social

What share of all stock conversation is about NERV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Mar 9

Minerva Neurosciences' ($NERV) stock is up 32% on a schizophrenia catalyst story, with a planned confirmatory Phase 3 program for its lead drug roluperidone.
The stock has broken through a key resistance level at $677.02, with abnormal volume validating the move, and a technical target projected at $1121.97.
Minerva Neurosciences is a clinical-stage biotech focused on CNS disorders, with its lead drug targeting negative symptoms of schizophrenia, and is participating in a sector conference that could provide further catalysts for the stock.

Generated by AI

Sentiment

Of the messages about NERV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.15% -12.12
Bearish	—	—	—	15.85% +12.12

Bullish· Mar 9

Minerva Neurosciences has broken through a key resistance level at $6.77, with a significant volume spike validating the move.
The company's participation in a recent conference has been seen as a catalyst for its stock, which has surged 33.11% to $8.00.
The stock's next measured move target projects to $11.22, indicating potential for further upside.

Bearish· Oct 21

The asset has been subject to a pump and dump scheme, with insiders potentially manipulating the price.
The stock's price has been heavily influenced by spammers and short sellers, leading to easy stop-losses and a correction.
The asset's price has been significantly impacted by the selling of bagholders, with the market potentially moving down to the $7.50 range.

Generated by AI

Topics

Of the messages about NERV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	12.76%
Announcements	—	—	—	25%
Controversies	—	—	—	0.91%
Earnings	—	—	—	0%
Macro	—	—	—	10.16%
Technical Analysis	—	—	—	51.17%

Announcements· Oct 21

Minerva Neurosciences, Inc. (NERV) has secured up to $200 million in funding to advance its Phase 3 confirmatory trial for roluperidone, a treatment for negative symptoms in patients with schizophrenia.
The financing includes an $80 million upfront Series A preferred stock sale, up to $80 million from Tranche A warrant exercises, and $40 million contingent on a milestone tied to Tranche B warrant cash exercises.
The proceeds from the financing are expected to fund the confirmatory Phase 3 trial, resubmission of the New Drug Application, and preparation for US commercial launch, if approved.

Controversies· Dec 29

Minerva Neurosciences, Inc. (NERV) is facing scrutiny after IronNet Announces Receipt of Notification Letter from NYSE, potentially indicating a listing issue.
The exact nature of the NYSE notification is unclear, but it has sparked concerns about the company's compliance and potential impact on its stock price.
The controversy surrounding NERV's listing status may have implications for investors and market analysts, highlighting the need for further information and clarification.

Technical Analysis· Mar 9

$NERV has broken through a key resistance level at $677.02, with abnormally high volume of 587,66K confirming the upward momentum.
The technical analysis suggests a projected target price of 1121.97, representing a potential upside of 33.11% from the current level.
The company's participation in a sector conference is seen as a catalyst for further price movement.

Generated by AI

Community

Of the messages about NERV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	36.21%
Newcomers	—	—	100%	63.79%

Regulars· Feb 28

Minerva Neurosciences, Inc. traded 3748% above average volume, with a -58.82% closing price decrease.
HC Wainwright has maintained a neutral rating for Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. was one of several companies mentioned in a list of financial results, including Zealand Pharma's 2023 full-year results.

Newcomers· Mar 9

Minerva Neurosciences' stock rose 32% as traders focused on the company's schizophrenia catalyst story, with its lead drug roluperidone targeting negative symptoms of the disorder.
The planned confirmatory Phase 3 program for roluperidone is a key setup for the stock, indicating a potential catalyst for further growth.
Minerva Neurosciences is a clinical-stage biotech focused on CNS disorders, with a lead drug targeting schizophrenia symptoms, making it a stock to watch for those interested in biotech and pharma.

Generated by AI

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside cha

1mo agoYahoo Finance

Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway

1mo agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME)

Detailed price information for Insmed Inc (INSM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Minerva Neurosciences: Q2 Earnings Snapshot

1mo agoYahoo Finance

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

1mo agoYahoo Finance

Also Discussed

Investors talking about NERV also mention

#	Name	Attention
1	Holley Inc.HLLY	0%0
2	B.O.S. Better Online Solutions Ltd.BOSC	0%0
3	Cellectar Biosciences, Inc.CLRB	0%new
4	GRFX - Graphex Group Limited	——
5	HPCO - Hempacco Co., Inc.	——
6	BioAffinity Technologies Inc.BIAF	0%+0
7	VACC - Vaccitech plc	——
8	ITCI - Intra-Cellular Therapies, Inc.	——
9	STBX - Starbox Group Holdings Ltd. Ordinary Shares	——
10	Intelligent Living Application Group Inc.ILAG	0%new

Minerva Neurosciences Inc.

Healthcare
Biotechnology

Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant. The company’s work is concentrated on advancing proprietary medicines through clinical development and regulatory pathways, with an emphasis on conditions where treatment options remain limited. Minerva Neurosciences serves a specialized role in the biopharmaceutical market by targeting neuropsychiatric and neurological diseases that affect patients, clinicians, and healthcare systems worldwide. Headquartered in Burlington, Massachusetts, Minerva Neurosciences operates as a research-driven company whose primary business is the development and commercialization of product candidates for complex brain and nervous system disorders.

Website

Location

1500 District Avenue

Burlington, MA, 01803

United States

Social

What share of all stock conversation is about NERV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Mar 9

Minerva Neurosciences' ($NERV) stock is up 32% on a schizophrenia catalyst story, with a planned confirmatory Phase 3 program for its lead drug roluperidone.
The stock has broken through a key resistance level at $677.02, with abnormal volume validating the move, and a technical target projected at $1121.97.
Minerva Neurosciences is a clinical-stage biotech focused on CNS disorders, with its lead drug targeting negative symptoms of schizophrenia, and is participating in a sector conference that could provide further catalysts for the stock.

Generated by AI

Sentiment

Of the messages about NERV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	84.15% -12.12
Bearish	—	—	—	15.85% +12.12

Bullish· Mar 9

Minerva Neurosciences has broken through a key resistance level at $6.77, with a significant volume spike validating the move.
The company's participation in a recent conference has been seen as a catalyst for its stock, which has surged 33.11% to $8.00.
The stock's next measured move target projects to $11.22, indicating potential for further upside.

Bearish· Oct 21

The asset has been subject to a pump and dump scheme, with insiders potentially manipulating the price.
The stock's price has been heavily influenced by spammers and short sellers, leading to easy stop-losses and a correction.
The asset's price has been significantly impacted by the selling of bagholders, with the market potentially moving down to the $7.50 range.

Generated by AI

Topics

Of the messages about NERV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	12.76%
Announcements	—	—	—	25%
Controversies	—	—	—	0.91%
Earnings	—	—	—	0%
Macro	—	—	—	10.16%
Technical Analysis	—	—	—	51.17%

Announcements· Oct 21

Minerva Neurosciences, Inc. (NERV) has secured up to $200 million in funding to advance its Phase 3 confirmatory trial for roluperidone, a treatment for negative symptoms in patients with schizophrenia.
The financing includes an $80 million upfront Series A preferred stock sale, up to $80 million from Tranche A warrant exercises, and $40 million contingent on a milestone tied to Tranche B warrant cash exercises.
The proceeds from the financing are expected to fund the confirmatory Phase 3 trial, resubmission of the New Drug Application, and preparation for US commercial launch, if approved.

Controversies· Dec 29

Minerva Neurosciences, Inc. (NERV) is facing scrutiny after IronNet Announces Receipt of Notification Letter from NYSE, potentially indicating a listing issue.
The exact nature of the NYSE notification is unclear, but it has sparked concerns about the company's compliance and potential impact on its stock price.
The controversy surrounding NERV's listing status may have implications for investors and market analysts, highlighting the need for further information and clarification.

Technical Analysis· Mar 9

$NERV has broken through a key resistance level at $677.02, with abnormally high volume of 587,66K confirming the upward momentum.
The technical analysis suggests a projected target price of 1121.97, representing a potential upside of 33.11% from the current level.
The company's participation in a sector conference is seen as a catalyst for further price movement.

Generated by AI

Community

Of the messages about NERV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	36.21%
Newcomers	—	—	100%	63.79%

Regulars· Feb 28

Minerva Neurosciences, Inc. traded 3748% above average volume, with a -58.82% closing price decrease.
HC Wainwright has maintained a neutral rating for Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. was one of several companies mentioned in a list of financial results, including Zealand Pharma's 2023 full-year results.

Newcomers· Mar 9

Minerva Neurosciences' stock rose 32% as traders focused on the company's schizophrenia catalyst story, with its lead drug roluperidone targeting negative symptoms of the disorder.
The planned confirmatory Phase 3 program for roluperidone is a key setup for the stock, indicating a potential catalyst for further growth.
Minerva Neurosciences is a clinical-stage biotech focused on CNS disorders, with a lead drug targeting schizophrenia symptoms, making it a stock to watch for those interested in biotech and pharma.

Generated by AI

Minerva Neurosciences

Social

Mar 9

Bullish· Mar 9

Bearish· Oct 21

Announcements· Oct 21

Controversies· Dec 29

Technical Analysis· Mar 9

Regulars· Feb 28

Newcomers· Mar 9

Minerva Neurosciences at Cantor conference: roluperidone reset

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME)

Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Also Discussed

Minerva Neurosciences Inc.

Company Information

Location

Minerva Neurosciences at Cantor conference: roluperidone reset

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME)

Minerva Neurosciences: Q2 Earnings Snapshot

Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates

Also Discussed

Social

Mar 9

Bullish· Mar 9

Bearish· Oct 21

Announcements· Oct 21

Controversies· Dec 29

Technical Analysis· Mar 9

Regulars· Feb 28

Newcomers· Mar 9